GH
Guardant Health, Inc.
September 15, 2026 · market open
- Rarity
- 1.06
- Peak move
- +6.31%
- Float cap
- $21.1B
Guardant Health is a precision oncology company that provides blood and tissue tests, real-world data, and AI analytics for cancer care. Its products are used for early cancer screening, recurrence monitoring, and treatment selection, and are sold to oncologists, health systems, biopharmaceutical companies, and screening providers.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
7 events · 3 from SEC or newswire · 0 timed with the move- Key event
clinical_readoutAstraZeneca's phase III Serena-4 trial testing camizestrant plus palbociclib as first-line treatment for HR-positive/HER2-negative advanced breast cancer missed statistical significance for progression-free survival versus anastrozole plus palbociclib, a result UBS said preserves ESR1 monitoring and companion-diagnostic demand for Guardant360.
insider_saleOfficer Darya Chudova filed notice to sell 7,738 shares of Guardant Health common stock at an average price of $178.00, a proposed sale dated September 15, 2026 valued at approximately $1.4 million.
SEC144 0001921094-26-001020analyst_ratingPiper Sandler reiterated an Overweight rating and $193 price target on Guardant Health, citing commercial coverage, the G360 Liquid CDx approval and camizestrant-related monitoring as 2027 growth drivers.
insider_saleDirector Alex M Azar II exercised options on 1,651 shares of Guardant Health on September 12, 2026.
SEC4 0001402256-26-000004insider_saleGuardant Health Chief Information Officer Kumud Kalia sold 4,000 shares at $158.05 for $632,193 on September 11, 2026, leaving him 39,794 shares directly.
SEC4 0001927831-26-000022Webgurufocus.com- Key event
regulatory_approvalGuardant Health's Shield blood test for colorectal cancer screening will be covered under EviCore by Evernorth, the Cigna-owned benefits manager, clinical guidelines effective January 1, 2027, extending coverage across 23 states and lifting total covered Shield lives for ages 45+ to about 94 million.
- Key event
executive_remarkAt the Morgan Stanley 24th Annual Global Healthcare Conference, Guardant Health co-CEO AmirAli Talasaz and CFO Mike Bell discussed Shield's category scaling, cost per test declining from over $400 in Q2 toward $350 by year-end with a $200 long-term target, a sales force expanding toward 600-700 reps, and reiterated a 2028 biopharma revenue target of about $300 million.